These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2776103)

  • 1. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
    Ho AD; del Valle F; Rückle H; Schwammborn J; Schlimok G; Hiddemann W; Meusers P; Thiel E; Dörken B; Hunstein W
    Cancer; 1989 Oct; 64(7):1388-92. PubMed ID: 2776103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
    Wang WS; Tzeng CH; Chiou TJ; Liu JH; Hsieh RK; Yen CC; Chen PM
    Jpn J Clin Oncol; 1997 Jun; 27(3):154-7. PubMed ID: 9255269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
    Wang WS; Tzeng CH; Chiou TJ; Liu JH; Fan S; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Feb; 57(2):100-5. PubMed ID: 8634923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.
    Ho AD; Del Valle F; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Haas R; Thiel E; Andreesen R; Fiedler W
    Cancer; 1990 Aug; 66(3):423-30. PubMed ID: 2194641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
    Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
    Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
    Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
    Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
    Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
    Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
    Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
    Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
    Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
    Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology.
    Gentet JC; Patte C; Quintana E; Bergeron C; Rubie H; Pein F; Demaille MC; Philip T; Raybaud C
    J Clin Oncol; 1990 Apr; 8(4):661-5. PubMed ID: 2313335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.
    Ruit JB; Löwenberg B; Hagenbeek A; Verhoef GE; Wielenga JJ; Michiels J; Sizoo W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):24-7. PubMed ID: 2259920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
    J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.